Unknown

Dataset Information

0

Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.


ABSTRACT:

Purpose

Despite superiority of tamsulosin-dutasteride combination therapy versus monotherapy for lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH), patients at risk of disease progression are often initiated on ?-blockers. This study evaluated the impact of initiating tamsulosin monotherapy prior to switching to tamsulosin-dutasteride combination therapy versus immediate combination therapy using a longitudinal model describing International Prostate Symptom Score (IPSS) trajectories in moderate/severe LUTS/BPH patients at risk of disease progression.

Methods

Clinical trial simulations (CTS) were performed using data from 10,238 patients from Phase III/IV dutasteride trials. The effect of varying disease progression rates was explored by comparing profiles on- and off-treatment. CTS scenarios were investigated, including a reference (immediate combination therapy) and six alternative virtual treatment arms (delayed combination therapy of 1-24 months). Clinical response (??25% IPSS reduction relative to baseline) was analysed using log-rank test. Differences in IPSS relative to baseline at various on-treatment time points were assessed by t tests.

Results

Delayed combination therapy initiation led to significant (p?ConclusionsCTS allows systematic evaluation of immediate versus delayed combination therapy. Immediate response to ?-blockers is not predictive of long-term symptom improvement. Observed IPSS differences between immediate and delayed combination therapy (6-24 months) are statistically significant.

SUBMITTER: D'Agate S 

PROVIDER: S-EPMC6994451 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.

D'Agate Salvatore S   Wilson Timothy T   Adalig Burkay B   Manyak Michael M   Palacios-Moreno Juan Manuel JM   Chavan Chandrashekhar C   Oelke Matthias M   Roehrborn Claus C   Della Pasqua Oscar O  

World journal of urology 20190511 2


<h4>Purpose</h4>Despite superiority of tamsulosin-dutasteride combination therapy versus monotherapy for lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH), patients at risk of disease progression are often initiated on α-blockers. This study evaluated the impact of initiating tamsulosin monotherapy prior to switching to tamsulosin-dutasteride combination therapy versus immediate combination therapy using a longitudinal model describing International Prostate Symptom Sco  ...[more]

Similar Datasets

| S-EPMC8332595 | biostudies-literature
| S-EPMC8481292 | biostudies-literature
| S-EPMC3739550 | biostudies-other
| S-EPMC3739107 | biostudies-other
| S-EPMC7564885 | biostudies-literature
| S-EPMC7204507 | biostudies-literature
| S-EPMC3094762 | biostudies-literature
| S-EPMC6534446 | biostudies-literature
| S-EPMC5696287 | biostudies-literature
| S-EPMC8143400 | biostudies-literature